Skip to main content

Table 3 Demographic and clinical characteristics of adult onset Still’s disease in elderly cases [4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41]

From: Adult onset Still’s disease in the elderly: a case-based literature review

Clinical Characteristics

Total (N, %)a

Patients with MASb (N, row %)

Patients without MAS (N, row %)

p-value*

Patient count

42 (100%)

10 (23.81%)

32 (76.19%)

 

AGE (YEAR), (MEDIAN, IQR)

75, 7

74.5, 8

75, 6

0.49

Female

34 (80.95%)

10 (23.81%)

24 (57.14%)

0.16

Fever

42 (100%)

10 (23.81%)

32 76.19%)

1.00

Rash

34 (80.95%)

10 (23.81%)

24 (57.14%)

0.16

Pruritic rash

9 (21.43%)

4 (9.52%)

5 (11.90%)

0.23

Arthralgia/Myalgia

38 (90.48%)

7 (16.67%)

31 (73.81%)

0.04

Serositis

7 (16.67%)

1 (2.38%)

6 (14.29%)

0.49

Hepatosplenomegaly

14 (33.33%)

3 (7.14%)

11 26.19%)

0.06

Sore throat

22 (52.38%)

6 (14.29%)

16 (38.10%)

0.31

Leukocytosis, (Median, IQR)

13,700, 8800

9000, 5895

16,000, 9470

< 0.01

Hyperferritinemia, (Median ± IQR)

5336, 15,447

41,932, 70,250

2684, 7821

< 0.01

Transaminitis

28 (66.67%)

7 (16.67%)

21 (50.0%)

1.00

Delayed Diagnosis (>  1 month)

38 (90.48%)

9 (21.43%)

29 (69.05%)

< 0.01

Corticosteroids

39 (92.36%)

9 (21.43%)

30 (71.43%)

0.28

NSAIDsc

14 (33.33%)

1 (2.38%)

13 (30.95%)

0.04

Conventional DMARDsd

17 (40.48%)

5 (11.90%)

12 (28.57%)

0.15

Biologic DMARDs

8 (19.05%)

3 (7.14%)

5 (11.90%)

0.09

Miscellaneous Treatment

8 (19.05%)

3 (7.14%)

5 (11.90%)

0.09

  1. a All percentages are based on the overall patients in total (42 patients)
  2. b MAS Macrophage activation syndrome
  3. c NSAIDs Nonsteroidal anti-inflammatory drugs
  4. c DMARDs Disease-modifying anti-rheumatic drugs
  5. * Wilcoxon rank sum test, Chi-square test, or Fisher’s exact test was applied where it is appropriate. Statistical tests used two-sided hypothesis testing